South Africa Group Wants ‘Truth’ Told About Vaping

News by Vapor Voice
Jul.20.2022

The head of the Vapour Products Association of South Africa (VPASA) says the booming sector is plagued by continual misinformation and disinformation despite scientific evidence demonstrating that vaping is less harmful than smoking.

South Africa Group Wants ‘Truth’ Told About Vaping

Chief executive of VPASA, Asanda Gcoyi said vaping is the single, most effective tool which can move smokers away from the deadly addiction to cigarettes, according to a story on IOL.

 

“We accept that vaping is not without risk, but it is a potentially less harmful alternative to smoking. What we cannot afford to do is to unduly stymie this technological innovation that can be the single most effective tool to move smokers away from their deadly addiction to cigarettes,” she said. “We have a collective responsibility to share correct information about vaping and other less harmful alternatives to smoking so that smokers can make an informed decision for their health.”

 

In the ongoing efforts to shed light and demystify vaping in South Africa, VPASA is on a drive to ultimately debunk some of the most prominent vaping myths circulating, according to Gcoyi.

 

The first myth is that vaping is as harmful as smoking.

 

“Although not risk-free, vaping is a potentially less harmful alternative to combustible tobacco. There are significantly lower levels of exposure to harmful chemicals in people who switch from smoking to vaping compared with those who continue to smoke,” she says. “The science that dates back as far as 2015 says vaping is a less harmful alternative to smoking, and recent updates continue to support this.”

 

The second myth is that vaping causes popcorn lung.

 

“According to Cancer Research UK, popcorn lung (bronchiolitis obliterans) is an uncommon type of lung disease, but it is not cancer,” says Gcoyi. “It is caused by a build-up of scar tissue in the lungs, which blocks the flow of air. E-cigarettes don’t cause the lung condition known as popcorn lung.”

 

Gcoyi said there was also a myth that vaping causes lung cancer.

 

“The fact is that burning tobacco in all its forms means exposure to carcinogenic chemicals. If you are a smoker, switching to vaping will reduce your risk of cancer. Most toxins from smoking are absent in electronic nicotine and non-nicotine delivery systems aerosol, she said. “Electronic non-nicotine delivery systems (ENDS) are a tool for consuming nicotine that is less harmful than if consumed via the combustion of tobacco. Coffee is brewed for caffeine. Vaping atomizes e-liquid for nicotine. Both caffeine and nicotine would [be harmful] if burned.”

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Product | “2+20” Configuration and Magnetic Semi-Enclosed Design: JNR Open-System E-cigarette Enters the UK Market
Product | “2+20” Configuration and Magnetic Semi-Enclosed Design: JNR Open-System E-cigarette Enters the UK Market
The e-cigarette brand JNR has recently launched its open-system product, JNR Whale, in the UK market, with the device now available through online retail channels such as Vape Sourcing and IDEA VAPE. The product features a 2+20 ml refillable configuration, combined with a dual mesh coil and a magnetic design, and is priced at approximately £11.99 across retail channels.
Dec.16 by 2FIRSTS.ai
JT Partners with Japan’s Year-End Music Festivals, Unveils Eight Limited-Edition Ploom AURA Front Panels
JT Partners with Japan’s Year-End Music Festivals, Unveils Eight Limited-Edition Ploom AURA Front Panels
Japan Tobacco Inc. (JT) will partner with two major year-end music festivals in Japan to set up “Ploom LOUNGE” smoking areas on-site, offering trial experiences of its Ploom AURA heated tobacco device. The company will also launch eight festival-exclusive front panels for Ploom AURA, distributed through on-site exchanges and a member lottery program.
Dec.11 by 2FIRSTS.ai
South Korea Plans Unified Regulation for Synthetic and Look-Alike Nicotine Products
South Korea Plans Unified Regulation for Synthetic and Look-Alike Nicotine Products
South Korea Parliament discusses including "nicotine" in Tobacco Business Act; synthetic nicotine testing method established, awaiting legislation approval.
Oct.22 by 2FIRSTS.ai
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G has launched the limited-edition “lil hybrid 3.0 Misty Rose Edition” heated tobacco device in South Korea, betting on year-end consumer demand with a gradient rose-colored design. The release is capped at 20,000 units and is available through both online and offline channels, with an official retail price of 78,000 won (approximately USD 53).
Nov.20 by 2FIRSTS.ai
KT&G Revises Partnership Terms with PMI, Secures Overseas Commercialization Rights for Multiple Heated Tobacco Platforms
KT&G Revises Partnership Terms with PMI, Secures Overseas Commercialization Rights for Multiple Heated Tobacco Platforms
KT&G has revised the terms of its 15-year partnership agreement with Philip Morris International (PMI), securing overseas commercialization rights for multiple heated tobacco platforms and adjusting the minimum guaranteed sales volume for lil-exclusive heated tobacco sticks from 16 billion units to 11 billion units.
Dec.12 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai